Dáil Éireann Debate, Tuesday - 30 April 2024
734. Deputy David Cullinane asked the Minister for Health the reason public funding of CAR-T immunotherapy for leukaemia patients is limited to under 26 years of age; if consideration has been given to extending the age for funding of treatment option to beyond the age of 26 years; and if he will make a statement on the matter. [19441/24]
View answer741. Deputy Mark Ward asked the Minister for Health the reason public funding of CAR-T immunotherapy for leukaemia patients is limited to under 26 years old; if consideration has been given to extending the age for funding of treatment option to beyond the age of 26 years; and if he will make a statement on the matter. [19470/24]
View answerI propose to take Questions Nos. 734 and 741 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
